Related Experiment Videos
Bactericidal properties of group IIA and group V phospholipases A2
J O Grönroos1, V J Laine, M J Janssen
1Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.
Abstract:
Group V phospholipase A(2) (PLA(2)) is a recently characterized 14-kDa secretory PLA(2) of mammalian heart and macrophage-derived cells. Group IIA PLA(2), which is structurally close to group V PLA(2), has been shown to kill Gram-positive bacteria in vitro and to prevent symptoms of Gram-positive infection in vivo. We studied the antibacterial properties of fully active recombinant rat group IIA and V PLA(2)s. Both group IIA and V PLA(2)s were highly bactericidal against Gram-positive bacteria, including methicillin-resistant staphylococci and vancomycin-resistant enterococci. Only high concentrations of group IIA PLA(2) showed some bactericidal effect against the Gram-negative bacterium Escherichia coli. Our results confirm that group IIA PLA(2) is a potent antibacterial enzyme against Gram-positive bacteria. Moreover, we show here that group V PLA(2) is a novel antibacterial mammalian protein, but is less potent than group IIA PLA(2). Both enzymes may be considered as future therapeutic agents against bacterial infections.
Insights
Group V phospholipase A(2) (PLA(2)) is a novel antibacterial protein effective against Gram-positive bacteria. This enzyme, along with Group IIA PLA(2), shows potential as a therapeutic agent for bacterial infections.
Area of Science:
- Biochemistry
- Microbiology
- Immunology
Background:
- Group V phospholipase A(2) (PLA(2)) is a 14-kDa secretory enzyme found in mammalian heart and macrophage-derived cells.
- Group IIA PLA(2), structurally similar to Group V PLA(2), exhibits antibacterial activity against Gram-positive bacteria.
- Existing research highlights the role of Group IIA PLA(2) in combating Gram-positive infections.
Purpose of the Study:
- To investigate and compare the antibacterial properties of recombinant rat Group IIA and Group V PLA(2)s.
- To determine the efficacy of these enzymes against various Gram-positive and Gram-negative bacteria.
- To evaluate the potential of Group IIA and Group V PLA(2)s as therapeutic agents.
Main Methods:
- Production of fully active recombinant rat Group IIA and Group V PLA(2)s.
- Testing the bactericidal activity of both enzymes against a panel of Gram-positive bacteria, including resistant strains.
- Assessing the antibacterial effect of high concentrations of Group IIA PLA(2) against Escherichia coli.
Main Results:
- Both Group IIA and Group V PLA(2)s demonstrated significant bactericidal activity against Gram-positive bacteria, including methicillin-resistant staphylococci and vancomycin-resistant enterococci.
- Group IIA PLA(2) exhibited some bactericidal effect against the Gram-negative bacterium Escherichia coli, but only at high concentrations.
- Group V PLA(2) was confirmed as a novel antibacterial mammalian protein, though less potent than Group IIA PLA(2).
Conclusions:
- Group IIA PLA(2) is a potent antibacterial enzyme against Gram-positive pathogens.
- Group V PLA(2) represents a newly identified antibacterial mammalian protein with potential therapeutic applications.
- Both Group IIA and Group V PLA(2)s warrant further investigation as future therapeutic agents for bacterial infections.